Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novartis recombinant meningococcal B vaccine with or without OMV in healthy infants
2006-005589-38Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2007
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of meningococcal group B vaccine (recombinant, adsorbed) in meningococcal disease and meningococcemia (2 arms), sponsored by Novartis. Primary endpoint: Immunogenicity by breadth of bactericidal activity after second and third dose. Started Jan 2007; status: completed.
02
Drugs
meningococcal group B vaccine (recombinant, adsorbed)
03
Conditions
meningococcal diseasemeningococcemia
Beyond the preview
Go deeper on 2006-005589-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005589-38.